Wise Will Seek FDA Approval for Digital Anxiety Management Therapy

Wise Will Seek FDA Approval for Digital Anxiety Management Therapy

290877

Wise Will Seek FDA Approval for Digital Anxiety Management Therapy

Wise Therapeutics intends to seek U.S. Food and Drug Administration (FDA) approval of an anxiety management therapy for multiple sclerosis (MS), following the positive results of a clinical trial. In addition to conducting a proof-of-concept study in MS, Wise tested its digital technique — called attention bias modification (ABM) treatment — in alcohol use disorder and for perinatal anxiety among pregnant women. A digital therapeutics company, Wise aims to obtain FDA clearance of its technique…

You must be logged in to read/download the full post.